Characterization of the T‐cell epitopes of a major peanut allergen, Ara h 2
- 2 November 2004
- Vol. 60 (1) , 35-40
- https://doi.org/10.1111/j.1398-9995.2004.00608.x
Abstract
The development of safe and effective immunotherapy for peanut allergy has been complicated by the high anaphylactic potential of native peanut extracts. We sought to map the T-cell epitopes of the major peanut allergen, Ara h 2 in order to develop T-cell targeted vaccines. A panel of eight peanut-specific CD4+ T-cell lines (TCL) was derived from eight peanut-allergic subjects and proliferative and cytokine responses to stimulation with a set of overlapping 20-mer peptides representing the entire sequence of Ara h 2 determined. Proliferation was assessed in 72 h assays via tritiated thymidine incorporation, while interleukin (IL)-5 and interferon (IFN)-gamma production were assessed via sandwich enzyme-linked immunosorbent assay (ELISA) of cell culture supernatants. Eight of the 17 Ara h 2 peptides were recognized by one or more subjects, with the two peptides showing highest reactivity [Ara h 2 (19-38) and Ara h 2 (73-92)] being recognized by three subjects each. Adjoining peptides Ara h 2 (28-47) and Ara h 2 (100-119) induced proliferative responses in two subjects. Each of these peptides was associated with a Th2-type cytokine response. Two highly immunogenic T-cell reactive regions of Ara h 2 have been identified, Ara h 2 (19-47) and Ara h 2 (73-119), providing scope for the development of safe forms of immunotherapy for peanut allergy.Keywords
This publication has 23 references indexed in Scilit:
- In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposureThe Journal of Experimental Medicine, 2008
- Anti-T-cell strategies in the treatment of allergic diseaseAllergy, 2002
- The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut‐allergic childrenClinical and Experimental Allergy, 2000
- Allergen immunotherapy: current and new therapeutic strategiesExpert Opinion on Investigational Drugs, 2000
- Peanut allergensAllergy, 1998
- Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challengeJournal of Allergy and Clinical Immunology, 1992
- Treatment of peanut allergy with rush immunotherapyJournal of Allergy and Clinical Immunology, 1992
- Regulation of the Immune Response to Allergens by Immunosuppressive Allergenic FragmentsInternational Archives of Allergy and Immunology, 1988
- PROPHYLACTIC INOCULATION AGAINST HAY FEVERPublished by Elsevier ,1911